Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD).
Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, Lapitz A, Izquierdo-Sanchez L, Bujanda L, Perugorria MJ, Banales JM, Rodrigues PM. Iturbe-Rey S, et al. Among authors: aspichueta p. Atherosclerosis. 2025 Jan;400:119053. doi: 10.1016/j.atherosclerosis.2024.119053. Epub 2024 Nov 14. Atherosclerosis. 2025. PMID: 39581063 Free article. Review.
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: aspichueta p. Aliment Pharmacol Ther. 2018 Dec;48(11-12):1260-1270. doi: 10.1111/apt.15015. Epub 2018 Oct 23. Aliment Pharmacol Ther. 2018. PMID: 30353552
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: aspichueta p. Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11. Clin Gastroenterol Hepatol. 2020. PMID: 31195161 Free article.
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P, Fernández-Ramos D, Lopitz-Otsoa F, Simón J, Barbier-Torres L, Gomez-Santos B, Nuñez-Garcia M, Azkargorta M, Gutiérrez-de Juan V, Serrano-Macia M, Rodríguez-Agudo R, Iruzubieta P, Anguita J, Castro RE, Champagne D, Rincón M, Elortza F, Arslanow A, Krawczyk M, Lammert F, Kirchmeyer M, Behrmann I, Crespo J, Lu SC, Mato JM, Varela-Rey M, Aspichueta P, Delgado TC, Martínez-Chantar ML. Fernández-Tussy P, et al. Among authors: aspichueta p. Mol Metab. 2019 Nov;29:40-54. doi: 10.1016/j.molmet.2019.08.008. Epub 2019 Aug 16. Mol Metab. 2019. PMID: 31668391 Free PMC article.
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: aspichueta p. J Hepatol. 2020 Jul;73(1):17-25. doi: 10.1016/j.jhep.2020.02.028. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147361
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, Rodrigues PM, Zhuravleva E, O'Rourke CJ, Hijona E, Jimenez-Agüero R, Riaño I, Landa A, La Casta A, Zaki MYW, Munoz-Garrido P, Azkargorta M, Elortza F, Vogel A, Schabbauer G, Aspichueta P, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. Esparza-Baquer A, et al. Among authors: aspichueta p. Gut. 2021 Jul;70(7):1345-1361. doi: 10.1136/gutjnl-2019-319227. Epub 2020 Sep 9. Gut. 2021. PMID: 32907830 Free PMC article.
Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Lee-Law PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, Rodrigues PM, Santos-Laso A, Azkargorta M, Elortza F, Martinez-Chantar ML, Perugorria MJ, Aspichueta P, Marzioni M, LaRusso NF, Bujanda L, Drenth JPH, Banales JM. Lee-Law PY, et al. Among authors: aspichueta p. J Hepatol. 2021 Feb;74(2):394-406. doi: 10.1016/j.jhep.2020.09.010. Epub 2020 Sep 17. J Hepatol. 2021. PMID: 32950589 Free PMC article.
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Colyn L, et al. Among authors: aspichueta p. Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642. Hepatology. 2021. PMID: 33222246
E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
González-Romero F, Mestre D, Aurrekoetxea I, O'Rourke CJ, Andersen JB, Woodhoo A, Tamayo-Caro M, Varela-Rey M, Palomo-Irigoyen M, Gómez-Santos B, de Urturi DS, Núñez-García M, García-Rodríguez JL, Fernández-Ares L, Buqué X, Iglesias-Ara A, Bernales I, De Juan VG, Delgado TC, Goikoetxea-Usandizaga N, Lee R, Bhanot S, Delgado I, Perugorria MJ, Errazti G, Mosteiro L, Gaztambide S, Martinez de la Piscina I, Iruzubieta P, Crespo J, Banales JM, Martínez-Chantar ML, Castaño L, Zubiaga AM, Aspichueta P. González-Romero F, et al. Among authors: aspichueta p. Cancer Res. 2021 Jun 1;81(11):2874-2887. doi: 10.1158/0008-5472.CAN-20-2052. Epub 2021 Mar 26. Cancer Res. 2021. PMID: 33771899
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: aspichueta p. Liver Int. 2021 Sep;41(9):2076-2086. doi: 10.1111/liv.14898. Epub 2021 May 7. Liver Int. 2021. PMID: 33896100 Free article.
96 results